Search results for Ganitumab

Ganitumab Biosimilar – Anti-IGF1R, CD221 mAb – Research Grade, ProteoGenix, PX-TA1123

Description of Ganitumab Biosimilar - Anti-IGF1R, CD221 mAb - Research Grade Introduction Ganitumab Biosimilar, also known as Anti-IGF1R, CD221 mAb, is a monoclonal antibody that targets the insulin-like growth factor 1 receptor (IGF1R) and is currently being developed as a potential therapeutic for various types of cancer. In this article, we will delve into the structure, activity, and potential applications of Ganitumab Biosimilar in the field of cancer research. Structure of Ganitumab Biosimilar Ganitumab Biosimilar is a recombinant monoclonal antibody that is produced using recombinant DNA technology. It is a humanized antibody, meaning that it is derived from non-human sources but has been modified to be more similar to human antibodies. The antibody has a molecular weight of approximately 150 kDa and is composed of two heavy chains and two light chains. The heavy chains contain four constant regions (Fc) and one variable region (Fab), while the light chains contain two constant regions and one variable region. The variable regions are responsible for the specificity of the antibody, as they bind to the target protein, IGF1R. Activity of Ganitumab Biosimilar The main target of Ganitumab Biosimilar is the IGF1R, a transmembrane receptor that is involved in cell growth, differentiation, and survival. IGF1R is overexpressed in various types of cancer, making it an attractive therapeutic target. Ganitumab Biosimilar binds to the extracellular domain of IGF1R and blocks the binding of insulin-like growth factors (IGFs), which are the natural ligands of IGF1R. This prevents the activation of downstream signaling pathways that promote cell growth and survival, ultimately inhibiting tumor growth. In addition to blocking IGF1R, Ganitumab Biosimilar also has an antibody-dependent cell-mediated cytotoxicity (ADCC) activity. This means that the antibody can bind to immune cells, such as natural killer (NK) cells, and activate them to kill cancer cells that express IGF1R. This dual mechanism of action makes Ganitumab Biosimilar a promising therapeutic agent for cancer treatment. Potential Applications of Ganitumab Biosimilar Ganitumab Biosimilar is currently being evaluated in clinical trials for the treatment of various types of cancer, including pancreatic, lung, and breast cancer. Preclinical studies have shown promising results in inhibiting tumor growth and enhancing the efficacy of other cancer treatments, such as chemotherapy and radiation therapy. One potential application of Ganitumab Biosimilar is in combination therapy with other targeted therapies. For example, IGF1R is often co-expressed with other therapeutic targets, such as epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2). Combining Ganitumab Biosimilar with inhibitors of these targets may have a synergistic effect in inhibiting tumor growth and improving patient outcomes. Another potential application of Ganitumab Biosimilar is in the treatment of drug-resistant cancers. IGF1R has been implicated in resistance to chemotherapy and targeted therapies, and Ganitumab Biosimilar may be able to overcome this resistance by targeting IGF1R. Conclusion In summary, Ganitumab Biosimilar is a promising monoclonal antibody that targets IGF1R and has the potential to be used as a therapeutic for various types of cancer. Its unique dual mechanism of action, targeting IGF1R and inducing ADCC, sets it apart from other targeted therapies and makes it a valuable addition to the arsenal of cancer treatments. Further clinical trials will determine the efficacy and safety of Ganitumab Biosimilar, and it may become an important tool in the fight against cancer.

Ganitumab, Abbexa, abx831081

Ganitumab is a monoclonal antibody biosimilar expressed in CHO cells, targeting IGF1R/CD221, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications. Ganitumab has been used in trials studying the treatment of Colon Cancer, Rectal Cancer, Breast Cancer, Breast Tumors, and Breast Neoplasms, among others.

Ganitumab ELISA Kit, ProteoGenix, KPTX160

Description of Ganitumab ELISA Kit Ganitumab ELISA Kit: Structure, Activity, and Application Ganitumab ELISA Kit: Structure, Activity, and Application Introduction Ganitumab is a human monoclonal antibody that specifically targets the insulin-like growth factor-1 receptor (IGF-1R). It has shown promising results in clinical trials as a potential therapeutic agent for various types of cancer. The Ganitumab ELISA Kit is a valuable tool for researchers to measure the levels of Ganitumab in biological samples, providing insights into its structure, activity, and potential applications. Structure of Ganitumab Ganitumab is a fully human IgG1 monoclonal antibody with a molecular weight of approximately 150 kDa. It is composed of two heavy chains and two light chains, each containing a variable region and a constant region. The variable region of Ganitumab binds to the extracellular domain of IGF-1R, while the constant region mediates its effector functions. The crystal structure of Ganitumab has been determined, revealing its binding mechanism to IGF-1R. The antibody binds to the ligand-binding site of the receptor, blocking the interaction between IGF-1 and IGF-1R. This leads to inhibition of downstream signaling pathways, ultimately resulting in inhibition of cell growth and survival in cancer cells. Activity of Ganitumab The primary activity of Ganitumab is its ability to specifically bind to IGF-1R and inhibit its activity. This results in decreased activation of downstream signaling pathways, such as the PI3K/Akt and MAPK pathways, which are crucial for cell growth and survival. Inhibition of these pathways leads to decreased proliferation and increased apoptosis in cancer cells. In addition, Ganitumab has also been shown to enhance the activity of other cancer treatments, such as chemotherapy and radiotherapy. This is due to its ability to sensitize cancer cells to these treatments, making them more susceptible to their effects. Application of Ganitumab ELISA Kit The Ganitumab ELISA Kit is a valuable tool for researchers to measure the levels of Ganitumab in biological samples. This can provide insights into the pharmacokinetics and pharmacodynamics of Ganitumab, as well as its potential efficacy and safety in clinical settings. The ELISA (enzyme-linked immunosorbent assay) is a commonly used technique for quantitative measurement of specific proteins in biological samples. The Ganitumab ELISA Kit utilizes a sandwich ELISA format, where the antibody is immobilized on a solid support and used to capture Ganitumab from the sample. A detection antibody labeled with an enzyme is then added, followed by a substrate that produces a colorimetric or fluorescent signal. The intensity of the signal is directly proportional to the amount of Ganitumab present in the sample. The Ganitumab ELISA Kit has been validated for use in various biological samples, including serum, plasma, and cell culture supernatants. It has a high sensitivity and specificity, making it a reliable tool for quantification of Ganitumab levels. This can aid in the development of dosing regimens and monitoring of treatment response in clinical trials. Conclusion The Ganitumab ELISA Kit is an essential tool for researchers studying the structure, activity, and potential applications of this promising therapeutic antibody. It provides a reliable and sensitive method for quantification of Ganitumab levels in biological samples, aiding in the understanding of its pharmacokinetics and pharmacodynamics. With ongoing clinical trials and potential future approvals, the Ganitumab ELISA Kit will continue to play a crucial role in the development and use of this therapeutic antibody.

Ganitumab ELISA Kit, Abbexa, abx395049

Ganitumab ELISA Kit is a quantitative ELISA kit for detection of Ganitumab.Ganitumab (AMG-479) is a mAb against IGF-IR which also inhibits binding of both IGF-1 and IGF-2 ligands to IGF-IR. The therapeutic value of AMG-479 was evaluated in several preclinical settings including androgen-dependent prostate cancer, and combined with androgen-deprivation therapy. Ganitumab was found to be most potent against VCaP xenografts when it was used in combination with complete androgen-deprivation therapy. After 4 weeks of treatment, tumor volume was reduced by 72% and growth suppression was maintained over 16 weeks of treatment. These findings suggested that the use of ganitumab in conjunction with androgen-deprivation therapy may be beneficial in the treatment of prostate cancer.

Ganitumab Biosimilar - Research Grade, ichor.bio, ICH5216

Detects IGF1R

Research Grade Ganitumab (HY353026), abinScience, HY353026